Table 4.
Baseline OMDS | Improved | No Change | Worsened | Total | ||||
---|---|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | n | ||
Steroids | 3 or 4 | 4 | 27 | 5 | 33 | 6 | 40 | 15 |
5 | 3 | 18 | 10 | 59 | 4 | 24 | 17 | |
6 or 7 | 6 | 55 | 5 | 45 | 0 | 0 | 11 | |
≥ 8 | 6 | 60 | 2 | 20 | 2 | 20 | 10 | |
Untreated | 3 or 4 | 1 | 8 | 6 | 50 | 5 | 42 | 12 |
5 | 0 | 0 | 4 | 57 | 3 | 43 | 7 | |
6 or 7 | 0 | 0 | 1 | 100 | 0 | 0 | 1 | |
≥ 8 | 0 | 0 | 3 | 60 | 2 | 40 | 5 |
Patients in the “Steroids” group were treated with prednisolone daily (or on alternating days), whereas those in the “Untreated” group were never treated during the period of evaluation. Data are summarized using patient counts and row percentages. Baseline OMDS refers to the OMDS at the start of each patient’s evaluation. Outcomes are classified as improved (decrease in OMDS), no change, or worsened (increase in OMDS). The Steroids and Untreated groups were compared using the van Elteren test with significance set at p < 0.05, and the resulting p-value was 0.019